Clinical
Trial
Eligibility

FORTITUDE-HCM is currently enrolling participants to evaluate the safety and efficacy of ninerafaxstat, an investigational medication, for the treatment of non-obstructive hypertrophic cardiomyopathy (nHCM).

Clinical trial sites across the United States are currently enrolling participants.